Virtual biopsy market seen reaching $1.23 billion by 2030

The virtual biopsy market is projected to grow from $0.79 billion in 2026 to $1.23 billion by 2030, according to The Business Research Company. Growth is being driven by cancer incidence, telemedicine adoption, and expanding use of AI-powered imaging in oncology and other specialties.

Why it matters: - Virtual biopsy offers a non-invasive alternative to traditional tissue sampling, which can reduce patient risk, discomfort and recovery time. - The market’s growth reflects broader demand for faster, safer diagnostic tools as healthcare shifts toward precision medicine and remote care.

What happened: - The Business Research Company published a Virtual Biopsy Market Report 2026 covering market size, trends and global forecasts through 2035. - The market is forecast to rise from $0.71 billion in 2025 to $0.79 billion in 2026. - The report projects the market will reach $1.23 billion by 2030. - The report pegs growth at a 11.9% CAGR in the historical period and 11.7% CAGR through 2030. - Download a free sample of the report. - View the full market report.

The details: - Virtual biopsy combines imaging technologies with computer algorithms to assess tissue abnormalities such as tumors or infections. - The method does not require physical extraction of tissue samples. - The report says the approach can deliver faster, safer and less painful diagnostics. - Rising cancer incidence is a major growth driver, with virtual biopsy positioned as a tool for diagnosis and monitoring. - Rock Health projected nearly two million new cancer cases in the United States in January 2023, up from about 1.9 million in 2022. - Telemedicine adoption is also accelerating demand because virtual biopsy can support remote tissue evaluation through imaging and AI-driven analysis. - Harmony Healthcare IT said in July 2023 that 62% of Americans had used telehealth services and 77% viewed it as the future of healthcare. - In 2025, North America held the largest share of the virtual biopsy market. - The Asia-Pacific region is expected to grow fastest during the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 report package includes market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, market hotspots infographics and updated graphics and tables.

Between the lines: - The forecast suggests virtual biopsy is moving from a niche diagnostic concept toward broader clinical adoption. - AI analytics, imaging algorithm improvements and links to personalized medicine appear to be the main technology tailwinds. - The regional outlook points to a mature North American market and faster uptake in Asia-Pacific as healthcare infrastructure and digital diagnostics expand.

What's next: - The market’s next phase will likely depend on whether imaging AI and remote-care workflows can keep improving diagnostic accuracy and accessibility. - Broader use in oncology, neurology, cardiovascular care and ophthalmology could expand the market beyond its current core applications. - Continued investment in research and diagnostic facilities is expected to support adoption through 2030 and beyond.

The bottom line: - Virtual biopsy is emerging as a faster, safer diagnostic option, and the market outlook points to steady double-digit growth through 2030.